HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ursodeoxycholic Acid

HCID 31401
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
128-13-2
Standard SMILES
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChIKey
RUDATBOHQWOJDD-UZVSRGJWSA-N
Molecular formula
C24H40O4
Average molar mass
392.6 g/mol
Monoisotopic mass
392.29265975

Overview

Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a mouse metabolite and a human metabolite. It is a C24-steroid, a dihydroxy-5beta-cholanic acid and a bile acid. It is a conjugate acid of an ursodeoxycholate.

Names & identifiers

Preferred name
Ursodeoxycholic Acid
IUPAC
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
English name
Ursodeoxycholic acid
Molecular formula
C24H40O4
Molecular weight
392.57

Names & synonyms

URSODEOXYCHOLIC ACIDursodiol128-13-2UDCAActigallUrsodesoxycholic acidUrso ForteDeursil3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acidAcido ursodeoxicolicoUrso 250Ursonorm
Show more names
UrsodeoxycholicURSODEOXYCHOLATETauroursodiol3-alpha,7-beta-dihydroxy-5-beta-cholanoicacidUrosodeoxycholic AcidPorcine deoxycholic acidurso
Acidum ursodeoxycholicum(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acidacide ursodeoxycholiqueDTXSID6023731724L30Y2QRDeoxyursocholic AcidNSC-683769

Database identifiers

CAS
128-13-2
PubChem CID
31401
DTXSID
DTXSID6023731

Properties

Computed structural properties

XLogP
4.9
Topological polar surface area
77.8 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
4
Rotatable bonds
4
Heavy atoms
28
Formal charge
0
Complexity
605

Experimental & physicochemical properties

Chemical ClassesBile Acids -> Quant Bile Acids
Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LipidsLipids -> Sterol Lipids [ST] -> Bile acids and derivatives [ST04] -> C24 bile acids, alcohols, and derivatives [ST0401]
LogP3.00
Solubility0.02 mg/mL
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Bile Acids and Salts; Cholagogues and Choleretics; Cholic Acids; Gastrointestinal Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 items

200-205

203 °C

Physical DescriptionSolid
Collision Cross Section · 5 items

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 4.5% (2 of 44) of reports.

Warning

H315 (95.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

REACH registered substance: Ursodeoxycholic acid (EC: 204-879-3)

Ursodeoxycholic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (95.5%)

Toxicology

Hepatotoxicity · 1 item

n multiple clinical trials in a variety of conditions, ursodiol has not been found to cause increases in serum enzyme elevations, worsening of underlying liver disease or clinically apparent liver injury. Nevertheless, there have been rare reports of clinical decompensation in patients with advanced liver disease and cirrhosis started on ursodiol, but the reason for such reactions is not known. In at least one instance, there was recurrence of jaundice on restarting ursodiol. Thus, ursodiol has beneficial effects on several forms of liver disease and has not been convincingly linked to cases of clinically apparent acute liver injury in patients without cirrhosis. There is some concern that ursodiol may be harmful in patients with advanced liver disease (Childs class B and C) and such patients probably should not receive ursodiol.

Chemistry & industry

Pharmacology

ATC Code · 3 items

A05AA02

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingUnconjugated ursodeoxycholic acid is at least 70% bound to plasma proteins in health individuals. There is no information regarding the protein binding of conjugated ursodeoxycholic acid.
Pharmacodynamics · 1 item

Ursodeoxycholic acid (UDCA) is a secondary bile acid with cytoprotectant, immunomodulating, and choleretic effects. It reduces the cholesterol fraction of biliary lipids. UDCA inhibits the absorption of cholesterol in the intestine and the secretion of cholesterol into bile, decreasing biliary cholesterol saturation. UDCA increases bile acid flow and promotes the secretion of bile acids.

Mechanism of Action · 1 item

Endogenous hydrophobic bile acids such as deoxycholic acid and chenodeoxycholic acid can exert hepatotoxic effects. Ursodeoxycholic acid is a hydrophilic bile acid that mediates its biological effects via several mechanisms. Ursodeoxycholic acid (UDCA) protects hepatocytes and cholangiocytes from bile acid-induced damage, such as reactive oxygen species (ROS)-induced inflammation and mitochondrial dysfunction. UDCA was shown to reserve hepatocyte cell structures and stimulate anti-apoptotic pathways. It was also shown to prevent the production of ROS by Kupffer cells and resident macrophages in the liver, thus attenuating oxidative stress in the liver. UDCA can also change the hydrophobicity index of the bile acid pool: following oral administration, UDCA forms a major fraction of the human bile acid pool and competitively displaces the hydrophobic or more toxic bile acids. It increases the absorption of hydrophilic bile acids. There are several proposed mechanisms of choleretic actions of UDCA: UDCA increases intracellular calcium levels, stimulating transport proteins and vesicular exocytosis in cholestatic hepatocytes. UDCA may also upregulate the expression of membrane transport proteins like the chloride-bicarbonate anion exchanger (AE2), which is involved in biliary secretion and is often observed to be defective in primary biliary cholangitis. In rats, UDCA reduced hepatic expression of major histocompatibility complex (MHC) class I antigens, suggesting immunomodulating effects. UDCA acts as a partial agonist at the bile acid receptor, also known as the farnesoid X receptor (FXR), and has negligible effects on cholesterol and lipid synthesis.

Related reactions

7 records
New reaction record
HRID 464235 reaction equation
HRID 464235As product
HRID 865406 reaction equation
HRID 865406As reactant
HRID 893896 reaction equation
HRID 893896As product
HRID 1153703 reaction equation
HRID 1153703As product
HRID 1659375 reaction equation
HRID 1659375As product
HRID 1721147 reaction equation
HRID 1721147As reactant
HRID 2371860 reaction equation
HRID 2371860As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEMBL
CHEMBL1551
ChEBI
CHEBI:9907
UNII
724L30Y2QR
EC Number
204-879-3
Nikkaji
J2.520H

200.0 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: Bile Acids]

208.98 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

198.7 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

186.8 Ų [M+H-2H2O]+ [CCS Type: DT; Method: single field calibrated]

198.86 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
203 · 203-204 °C (lit.)
alpha
60 · 60 º (c=2, EtOH)
Boiling point
437.26 °C · 437.26°C (rough estimate)
Density
0.9985 · 0.9985 (rough estimate)
refractive index
60.5 ° · 60.5 ° (C=2, EtOH)
Flash point
9 ℃ · 9℃
storage temp.
2 · 2-8°C
solubility
50 mg/mL, · ethanol: 50 mg/mL, clear
pka
5.04 · pKa 5.04±0.04(H2O t = 25.0±0.1 I = 0.00)(Approximate)
form
Solid. Powder.
color
White - almost white.
Water Solubility
practically insoluble
Merck
14 · 14,9889
BRN
3219888 · 3219888
Cosmetics Ingredients Functions
SKIN CONDITIONING - MISCELLANEOUSSKIN PROTECTING
InChIKey
RUDATBOHQWOJDD-UZVSRGJWSA-N
SMILES
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
LogP
3 · 3-3.38 at 20℃
CAS DataBase Reference
128 · 128-13-2(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
ursodiol
FDA UNII
724 L30Y2QR · 724L30Y2QR
NCI Drug Dictionary
Actigall
ATC code
5 AA02 · A05AA02
UNSPSC Code
41116107 · 41116107
NACRES
25 · NA.25
Protein binding
96 · 96-98%
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319
Precautionary statements
264 · P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313
PPE
95 · Eyeshields, Gloves, type N95 (US)
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
24 · 24/25-36-26
RIDADR
1230 · UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany
2 · 2
RTECS
2000000 · FZ2000000
F
10 · 10
HS Code
29181990 · 29181990
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 Skin · Eye Irrit. 2Skin Irrit. 2
Toxicity
50 in · LD50 in mice (g/kg): 0.1 i.v. (Ardenne, Reitnauer); in rats, mice (mg/kg): 2000, 6000 s.c.; 1000, 1200 i.p., 310, 260 i.v. (Ward)
REACH Registrations
Active
Adverse Effects · 1 item

UDCA is a mostly well-tolerated drug. In most clinical trials, diarrhea was the most frequent adverse event observed during UDCA treatment in patients with gallstone disease, with a reported incidence of 2 to 9%. The mechanism behind this side effect is unclear. However, researchers have proposed that bacterial conversion of UDCA to chenodeoxycholic acid, which serves as a potent secretory substance, could significantly contribute to this side effect. In patients with primary biliary cirrhosis, right upper quadrant abdominal pain was the most commonly reported side effect. Reports also exist of skin reactions in those with primary biliary cirrhosis. The most common dermatological manifestation was an exacerbation of pruritus, even though UDCA has demonstrated effectiveness in relieving pruritus in patients with PBC in other trials.

Toxicity Summary · 1 item

UDCA has been shown to have potentially toxic molecular properties. UDCA breaks down into toxic lithocholic acid. After being absorbed in the small intestine, UDCA undergoes hepatic conjugation. Beyond conjugation, UDCA does not experience further breakdown by the liver or intestinal mucosa. It becomes oxidized or reduced, yielding either 7-keto-lithocholic acid or lithocholic acid. Litcholic acid can be toxic to liver cells and even cause liver failure in those with compromised sulfation. It also leads to segmental bile duct injury, hepatocyte failure, and death.

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ursodiol

Ambiguous-DILI-concern

0

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

F
10
PPE
Eyeshields, Gloves, type N95 (US)
wgk
2
rtecs
FZ2000000
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
29181990
Toxicity
LD50 in mice (g/kg): 0.1 i.v. (Ardenne, Reitnauer); in rats, mice (mg/kg): 2000, 6000 s.c.; 1000, 1200 i.p., 310, 260 i.v. (Ward)
risk_code
36/37/38
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xi
safety_code
24/25-36-26
Storage Class
11 - Combustible Solids
Hazard statements
H315-H319
REACH Registrations
Active
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2
Precautionary statements
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313
Biological Half-LifeThe estimated half-life ranges from 3.5 to 5.8 days.
Metabolism/Metabolites · 1 item

Upon administration, ursodeoxycholic acid (UDCA) enters the portal vein and into the liver, where it undergoes conjugation with glycine or taurine. UDCA is also decreased into bile. Glycine or taurine conjugates are absorbed in the small intestine via passive and active mechanisms. The conjugates can also be deconjugated in the ileum by intestinal enzymes, leading to the formation of free UDCA that can be reabsorbed and re-conjugated in the liver. Nonabsorbed UDCA passes into the colon, where it undergoes 7-dehydroxylation by intestinal bacteria to lithocholic acid. Some UDCA is epimerized to [chenodeoxycholic acid] via a 7-oxo intermediate. Chenodeoxycholic acid also undergoes 7-dehydroxylation to form lithocholic acid. These metabolites are poorly soluble and excreted in the feces. A small portion of lithocholic acid is reabsorbed, conjugated in the liver with glycine or taurine, and sulfated at the 3 position. The resulting sulfated lithocholic acid conjugates are excreted in bile and then lost in feces.

FDA Pharmacological Classification · 6 items

724L30Y2QR

URSODIOL

Established Pharmacologic Class [EPC] - Bile Acid

Chemical Structure [CS] - Bile Acids and Salts

Ursodiol is a Bile Acid.

URSODIOL

MeSH Pharmacological ClassificationGastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).
Absorption, Distribution and Excretion · 3 items

Normally, endogenous ursodeoxycholic acid constitutes a minor fraction (about 5%) of the total human bile acid pool. Following oral administration, the majority of ursodiol is absorbed by passive diffusion, and its absorption is incomplete. Once absorbed, ursodiol undergoes hepatic extraction to about 50% in the absence of liver disease. As the severity of liver disease increases, the extent of extraction decreases. During chronic administration of ursodiol, it becomes a major biliary and plasma bile acid. At a chronic dose of 13 to 15 mg/kg/day, ursodiol constitutes 30-50% of biliary and plasma bile acids.

Ursodeoxycholic acid is excreted primarily in the feces. Renal elimination is a minor elimination pathway. With treatment, urinary excretion increases but remains less than 1% except in severe cholestatic liver disease.

The volume of distribution of ursodeoxycholic acid (UDCA) has not been determined; however, it is expected to be small since UDCA is mostly distributed in the bile in the gallbladder and small intestines.

Tissue LocationsAdrenal Cortex
Cellular LocationsExtracellular

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >10000
Applications · 3 items

UsesUrsodeoxycholic acid is a naturally occurring bile salt in humans. It is rapidly absorbed in the small intestine and excreted with the bile. Ursodeoxycholic acid is the drug of choise for the treatment of primary biliary cirrhosis and primary sclerosis cholanyitis. The daily dose amounts to 10-15 mg/kg. It has no side effects even after a treatment period of up to 20 years.Dissolution of gallstones. Mainly used for the treatment of inoperable cholesterol gallstones, it will have a cure rate especially in the case when gallbladder is basically normal, stones have a 15mm or lower diameters, X-ray penetrable, non-calcified and high-floating cholesterol stones.Ursodeoxycholic acid can also improve the efficacy of α-interferon on treatment of chronic hepatitis C. It can also used to treat diarrhea, rare constipation, allergic reactions, itching, headache, dizziness, stomach pain, pancreatitis and bradycardia Patients of completely biliary obstruction or severe liver dysfunction and pregnant women should avoid using.

UsesUrsodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response. It is also used as an anticholelithogenic. Epimer with Chenodiol with respect to the hydroxyl group at C7.

General DescriptionUrsodeoxycholic acid (UDCA) is a secondary bile acid that helps regulate cholesterol. Mass spectrometry-based analysis of UDCA is routinely performed in clinical diagnostic testing applications such as neonatal testing of inborn errors of bile acid synthesis, differentiating among types of familial intrahepatic cholestasis, and therapeutic monitoring of patient responses to UDCA therapy. This Certified Spiking Solution is suitable as a starting material in preparation of linearity standards, calibrators, and controls for use in LC-MS/MS and GC/MS bile acid testing methods.

Upstream & downstream products

Upstream raw materials

Diethylene glycol2,3-ButanedioneChenodeoxycholic acidCholic acid methyl esterPotassium chromateMethanolAcetylcholic acid5β-Cholanic acidAcetic acidHydrochloric acidChromium(VI) oxideSodium

Downstream products

24-norursodeoxycholic acidEthyl UrsodeoxycholateTauroursodeoxycholic acid sodium salt
Additional notes · 1 item

DefinitionChEBI: Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a human metabolite and a mouse metabolite. It is a bile acid, a dihydroxy-5beta-cholanic acid and a C24-steroid. It is a conjugate acid of an ursodeoxycholate.